(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Netanyahu vows to ‘return Negev to Israel,’ pledges settlement growth during visit - 2Extraordinary Miracles: The Cherished Islands for a Tropical Get-away
- 3Cannabis reclassification could 'open the floodgates' for research, scientists say
- 4Israeli archaeologists launch project to trace origins of ancient pottery
- 5New peace laureate: Iran's arrest of Mohammadi 'confession of fear'
- Nearly half of reindeer have been wiped out and armadillos are in Iowa. Here’s how animals are weathering warming holidays
- Nuno Loureiro, MIT physicist, fatally shot at home; police investigate
- Tech for Efficiency: Applications and Apparatuses to Accomplish More
- Germany records first wolf bite on human since repopulation
- Which Startup's Innovation Could Reform Medical care?
- A 3-limbed Kemp's ridley sea turtle is now being tracked at sea by satellite
- IVE 2026 'Show What I Am' Tour: How to get tickets, prices, dates and more
- Vote in favor of your Favored sort of footwear
- At least 7 dead as Israel renews attacks on Beirut and across Lebanon
